ANI Pharmaceuticals beats Q2 revenue, EPS beats estimates and raises FY forecast

Overview

• ANI Pharmaceuticals Q2 net revenues rise 53.1% yr/yr to $211.4 mln

• Adjusted EPS for Q2 beats consensus, reaching $1.80, per LSEG data

• Company raises 2025 guidance, expecting higher net revenues and EPS

Outlook

• Company expects 2025 net revenues of $818 mln to $843 mln

• ANI Pharmaceuticals sees 2025 adjusted EBITDA of $213 mln to $223 mln

• Company anticipates Rare Disease revenues to be 57% of total in H2 2025

• ANI forecasts 2025 non-GAAP EPS of $6.98 to $7.35

Result Drivers

• RARE DISEASE GROWTH - Cortrophin Gel net revenues increased 66% yr/yr, driven by higher prescription demand and new patient starts

• GENERIC LAUNCHES - Generics revenues rose 22.1% yr/yr, fueled by new product launches and operational excellence

• OPHTHALMOLOGY EXPANSION - Enhanced sales team and marketing efforts boosted ophthalmology segment, contributing to revenue growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for ANI Pharmaceuticals Inc is $84.00, about 17.8% above its August 7 closing price of $69.01

• The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nGNXnQHfm